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Abstract
Background: Closed-loop technology may help address health disparities experienced by adolescents, who are more 
likely to have suboptimal glycemic control than other age groups and, because of their age, find diabetes self-management 
particularly challenging. The CamAPS FX closed-loop has sought to address accessibility and usability issues reported by 
users of previous prototype systems. It comprises small components and a smartphone app used to: announce meal-time 
boluses, adjust (“boost” or “ease-off”) closed-loop insulin delivery, customize alarms, and review/share data. We explored 
how using the CamAPS FX platform influences adolescents’ self-management practices and everyday lives.
Methods: Eighteen adolescents were interviewed after having ≥6 months experience using the closed-loop platform. Data 
were analyzed thematically.
Results: Participants reported feeling less burdened and shackled by diabetes because closed-loop components were easier 
to carry/wear, finger-pricks were not required, the smartphone app provided a discreet and less stigmatizing way of managing 
diabetes in public, and they were able to customize alarms. Participants also reported checking and reviewing data more 
regularly, because they did so when using the smartphone for other reasons. Some reported challenges in school settings 
where use of personal phones was restricted. Participants highlighted how self-management practices were improved because 
they could easily review glucose data and adjust closed-loop insulin delivery using the “boost” and “ease-off” functions. Some 
described how using the system resulted in them forgetting about diabetes and neglecting certain tasks.
Conclusions: A closed-loop system with small components and control algorithm on a smartphone app can enhance 
usability and acceptability for adolescents and may help address the health-related disparities experienced by this age group. 
However, challenges can arise from using a medical app on a device which doubles as a smartphone.
Trial registration: Closed Loop From Onset in Type 1 Diabetes (CLOuD); NCT02871089; https://clinicaltrials.gov/ct2/
show/NCT02871089
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Introduction
A closed-loop system is a rapidly evolving technology for 
people with diabetes, which requires varying degrees of user 
input; for example, to calibrate the continuous glucose moni-
tor (CGM) or count carbohydrates and input this information 
prior to eating. Trials of early iterations of this technology 
were undertaken overnight, with the control algorithm hosted 
on a laptop or tablet.1,2 More recently, trials in real-life set-
tings have investigated day-and-night use with the algorithm 
hosted on the pump itself, or on a portable handheld device 
or smartphone,3,4 including the Medtronic 670G5 and the 
Tandem T-slim pump with Control-IQ,6 which are used in 
clinical practice in the United States and Europe.
Health-related disparities are often attributed to demo-
graphic factors, such as socioeconomic status or ethnicity, 
but can also be age related.7 Adolescents with type 1 diabe-
tes experience higher HbA1c levels than individuals in 
other age groups,8 leading to an increased risk of develop-
ing diabetic ketoacidosis9 and premature mortality.10 These 
age-related health disparities have been attributed to factors 
that make diabetes self-management particularly challeng-
ing in this age group, including peer group influences, fam-
ily conflict, greater risk-taking, and “diabetes burnout.”11-14 
Adolescents also experience greater prevalence of anxiety, 
depression, and disordered eating,15 which can further com-
pound difficulties undertaking self-management tasks and 
ensuing health disparities.
Evaluations of closed-loop technology involving adoles-
cents have demonstrated improved blood glucose control and 
decreased frequency of hypoglycaemia,1,2,4,16-21 including in 
adolescents with suboptimal glycemic control.18 While this 
kind of technology therefore has potential to address health-
related disparities in the adolescent age group, barriers to 
using this and related (eg, CGM, pump) technology have 
been reported, which can lead to discontinuation or low 
closed-loop use among adolescent users.20,22-25 These include 
concerns about: wearing large CGM and/or pump compo-
nents25-27; using bulky phone handsets that are awkward to 
carry and easy to forget, often resulting in system connectiv-
ity issues21-23; needing to perform excessive finger-prick 
checks, including to calibrate the CGM20,25-29; and “alarm 
fatigue” resulting from these being too frequent and intru-
sive.20,25-30 Adolescents, like adult users,31 have also expressed 
a desire to collaborate with the system by being able to 
instruct the algorithm when routines change or an atypical 
day is planned.13,29,31
A recently developed iteration of closed-loop technology, 
CamAPS FX,32 has taken account of user feedback and com-
prises: a CGM (Dexcom G6) that does not require calibration, 
a smaller pump (Dana RS), and a control algorithm hosted 
within an app on an unlocked Android smartphone. The closed-
loop app includes functions that enable users to: announce 
meal-time boluses, issue commands to increase (“boost”) or 
decrease (“ease-off”) closed-loop insulin delivery, switch on/
off and customize alarms, review their data history onscreen, 
and share data in “real-time” with health professionals and par-
ents/caregivers. In this article, we report findings from a quali-
tative evaluation involving adolescents who had ≥6 months 
experience of using the CamAPS FX platform. Specifically, we 
sought to explore how using the closed-loop system influences 
adolescents’ self-management practices and lives.
Methods
We used an inductive, semi-structured interview design that 
enabled the discussion to remain relevant to addressing the 
study aims while giving participants flexibility to discuss issues 
they considered salient, including those unforeseen at study out-
set. A topic guide was used (see Table 1), which was informed 
by literature reviews and inputs from patient representatives and 
clinical co-investigators. Data collection and analysis took place 
concurrently so that findings identified in early interviews could 
inform the topics explored in later accounts.
Recruitment and Data Collection
Individuals were recruited following randomization to a 
24-month open-label, UK-based, multicenter trial, followed 
by an optional 24-month extension phase, designed to assess 
the clinical effects of closed-loop insulin delivery compared 
with a multiple daily injection (MDI) regimen, in youths 
(aged 10-16.9 years) from onset of type 1 diabetes.32 
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Participants in the intervention arm began by using the previ-
ous prototype, FlorenceM closed-loop, before transiting to 
the CamAPS FX platform; both systems used the same con-
trol algorithm (see Table 2 for more detail about the trial and 
closed-loop systems).
Participants randomized to the closed-loop arm were 
recruited into the interview study by health professionals 
from six participating UK sites using an opt-in procedure. 
Purposive sampling was used to ensure diversity in adoles-
cents’ gender, age, and parental occupation (as a proxy for 
socioeconomic status). Recruitment and data collection con-
tinued until no new findings were identified in new data col-
lected (data saturation). Interviews were conducted by DR, 
an experienced nonclinical qualitative researcher. DR made 
it clear to participants that he was an independent researcher 
and that their participation in the interview study would not 
affect their clinical care. This information was provided to 
help ensure participants felt able to share negative views 
about using the closed-loop should they wish to do so. 
Interviews were conducted at a time of participants’ choos-
ing between November 2019 and March 2020. These were 
audio-recorded, lasted 1-1.5 h, and were transcribed in full.
The study received approval from Cambridge East 
Research Ethics Committee (REC ref: 16/EE/0286) and the 
Medicines & Health products Regulatory Agency.
Data Analysis
The interviews were analyzed by DR and JL using the method 
of constant comparison33 to identify cross-cutting themes. 
Both researchers read interviews repeatedly before undertak-
ing preliminary analyses and writing separate reports. Regular 
meetings were held to compare interpretations and reach 
agreement on a coding framework, which captured key 
themes. A qualitative data-indexing package, Nvivo11 (QSR 
International, Doncaster, Australia), was used to facilitate 
data coding and retrieval. Coded datasets were subjected to 
further analyses to allow more nuanced interpretations of the 
data and identify illustrative quotations.
Results
The sample comprised 18 adolescents, and demographic data 
are presented in Table 3. We identified several cross-cutting 
themes that illustrate how using the closed-loop platform: 
lessened the burdens of self-management and helped to nor-
malize participants’ lives; facilitated opportunities to moni-
tor and review data; enabled them to collaborate with the 
system to optimize glucose control; and provided options to 
customize alarms. We also report participants’ accounts of 
unintended consequences resulting from using the system. 
When reflecting on their experiences of using the CamAPS 
FX platform participants drew on earlier experiences using 
the FlorenceM closed-loop, which was their main basis for 
comparison following diagnosis and recruitment to the trial.
Benefits: Less Work, Feeling More Normal, and 
Less Stigmatized
All participants reported needing to do “much less work” 
(Participant#3) using the new closed-loop system because the 
G6 sensor gave “really accurate” (Participant#9) glucose 
readings, which meant they did not need to perform finger-
pricks for calibrations, before meals, after correcting high 
readings or treating hypoglycemia. As they highlighted, using 
the app to check glucose levels resulted in them feeling less 
shackled by diabetes because “you don’t have to be taking 
round bits of stuff, like a testing kit” (Participant#2) and “I 
don’t do any [finger-pricks] at all which is better and then 
they [parents] don’t have to nag me to do them” (Participant#6). 
Individuals also described how relationships with parents had 
improved because they could remote monitor their data and, 
hence, no longer burdened them with requests to provide this 
information (see Table 4).
Most also observed how diabetes had receded into the 
background by virtue of the G6 sensor being easier to wear: 
“it stays on so much better, it’s just smaller” (Participant#3) 
and only needing to be replaced every 10 days, while the 
Dana RS pump was “smaller and lighter” (Participant#16), 
“easier to fit in your pocket” (Participant#4), and did not 
need to be accessed to administer insulin. Indeed, many 
recalled the cumbersome process of having to “untangle 
yourself” (Participant#1) or “fumble about in your pocket” 
(Participant#3) to retrieve their pump to manage diabetes 
Table 1. Relevant Areas Explored in Interviews.
•  Background information: age, living arrangements, everyday 
school and family life; interests and hobbies, views about using 
technology in everyday life.
•  Views about and experiences of using the CamAPS FX closed-
loop to manage diabetes in everyday life at and away from 
home:
-  Inserting cannulas and CGM sensors, using the study 
pump, wearing devices on the body, using the study 
smartphone and app; ensuring devices are connected.
-  Using the app to monitor blood glucose levels; using 
finger-pricks to monitor blood glucose.
-  Using data on app to inform decisions about diabetes 
management tasks (eg, insulin administration, treating 
hypoglycemia, responding to high glucose levels).
- Managing hypo- or hyperglycemia.
-  Reasons for using the “Boost” and “Ease-off” functions; 
use of corrective doses of insulin.
-  Reasons for activating/deactivating and/or customizing 
system-generated alarms; and responses to these.
•  Perceived impact of using the closed-loop on self-perceptions, 
relationships with others and everyday life, including when at 
school or in other educational settings.
Abbreviation: CGM, continuous glucose monitor.
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using the previous system, whereas the app enabled them to 
check glucose levels and administer insulin effortlessly (see 
Table 4). Participants also noted how having the closed-loop 
app reside on a smartphone offered a more discreet and less 
stigmatizing way of performing these tasks in public, because 
other people construed that they were undertaking normal 
activities, such as checking the time or texting (see Table 4).
Better Opportunities to Monitor and Review 
Glucose Readings
All participants noted how having the app on an unlocked 
smartphone, which they could use as their personal phone, 
meant it was always kept close-to-hand or carried on their 
person. As a result, they described using the app to monitor 
Table 2. Trial Eligibility Criteria and Description of Closed-loop Systems.
Trial eligibility criteria
Eligibility criteria for the trial included: a diagnosis of type 1 diabetes within the preceding 21 days; aged between 10 and 16.9 years old; 
and a willingness to perform capillary blood glucose monitoring (at least four blood glucose measurements each day), wear study 
devices (glucose sensor and closed-loop system), and upload pump and CGM data at regular intervals.
Closed-loop systems used during the trial
Participants in this qualitative study began by using the FlorenceM hybrid closed-loop system before transiting to the CamAPS FX hybrid 
closed-loop platform. The control algorithm is the same for both systems.
FlorenceM hybrid closed-loop system CamAPS FX hybrid closed-loop platform
•  Modified next generation sensor augmented Medtronic insulin 
pump 640G (Medtronic, Northridge, CA, USA) with CGM 
receiver and low glucose suspend feature.
• Dana RS insulin pump (Diabecare, Sooil, Seoul, South Korea).
• Guardian 3 sensor (Medtronic). •  Dexcom G6 real-time CGM sensor (Dexcom, San Diego, 
CA, USA).
•  A locked-down Android smartphone (Galaxy S4, Samsung, 
South Korea) hosting the Cambridge model predictive 
control algorithm (University of Cambridge, Cambridge, 
UK) connected to a propriety translator to allow wireless 
communication with the insulin pump.
•  An unlocked Android smartphone (Galaxy S8, Samsung, South 
Korea) running Android 5.0 OS or above, which hosted 
the CamAPS FX Application incorporating the Cambridge 
model predictive control algorithm (University of Cambridge, 
Cambridge, UK) and communicating wirelessly with the 
insulin pump. Participants could opt to use their personal 
smartphone if compatible.
•  FlorenceM Users were required to: use a standard bolus 
calculator on the pump to enter information about 
carbohydrates and deliver meal boluses; change their pump 
infusion set every 2-3 days; replace the CGM sensor at least 
every 7 days; perform four finger-pricks per day before meals 
and to calibrate the sensor as required; respond to alarms 
alerting them to high/low blood glucose or if they needed 
to recalibrate the sensor; ensure that study devices (CGM 
transmitter and smartphone) are charged; and ensure the 
smartphone is kept in close proximity (5-10 meters) to avoid 
signal loss with the pump/CGM. Users could choose to activate 
an “exercise” function on the pump to deliver an extended 
bolus dose of insulin during periods of physical activity.
•  CamAPS FX Users were required to: use the bolus calculator 
on the app to deliver meal boluses; change their pump 
infusion set every 2-3 days; replace the CGM sensor at least 
every 10 days; respond to alarms alerting them to high/
low blood glucose; ensure that study devices (smartphone) 
are charged; and ensure the smartphone is kept in close 
proximity (5-10 m) to avoid signal loss with the pump/CGM. 
Further detail about the CamAPS FX app is provided below.
CamAPS FX app
In addition to being used to administer mealtime boluses of insulin, the app included functions enabling users to:
•  view a “real-time” graph displaying their sensor glucose levels, rate of insulin delivery, meal-time boluses and carbohydrate intake, 
high/low glucose range, glucose trend arrows, whether “boost” or “ease-off” functions were activated (see below), and whether the 
closed-loop was operational (Auto mode on) or interrupted (Auto mode off).
•  view summary statistics for daily, weekly, monthly, or three-monthly periods, including: average glucose, estimated HbA1c, time in/
below/above target, number and average duration of hypos, total daily dose/bolus/basal insulin, and percentage of time in Auto Mode.
•  issue instructions to the closed-loop to initiate a “Boost” mode of operation when more insulin was needed (eg, during periods of 
inactivity, increased food intake, or during illness or stress), or an “Ease-off” mode when less insulin was needed (eg, during exercise 
or when glucose levels tend to be low).
•  receive and personalize alarms/alerts triggered by high/low glucose, and signal loss with the sensor and/or pump, by adjusting the 
threshold, repeat time and audio sound or vibration, which accompanied an on-screen display, and turn on/off all alerts (except the 
“Urgent Low” glucose alarm).
•  share (by automatically uploading to the cloud) with health professionals, and their parents/caregivers, near “real-time” glucose levels, 
insulin, and meal-time bolus data, which could be accessed using the Diasend/Glooko app, and an option to relay alarms activated by 
users to a user-determined set of “followers” alerting them to high/low blood glucose, sent via SMS texts.
Abbreviation: CGM, continuous glucose monitor.
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their glucose levels more frequently than had happened when 
using the previous system because this could be done oppor-
tunistically while using the phone for other reasons, such as 
checking social media or making calls (see Table 4). 
Participants also reported how having the app on a smart-
phone meant they had easy access to a graph, which dis-
played a real-time record of their glucose levels, insulin on 
board, and carbohydrate intake: “if you need to take your 
insulin, or have a look at your bloods, you can see your chart 
[graph]” (Participant#13). As they noted, reviews of these 
data helped inform adjustments, such as identifying times to 
take preventative quick-acting carbohydrate to counter fall-
ing glucose levels, or refining carbohydrate calculations for 
meals (see Table 4). Others observed that always carrying the 
study phone meant they did not experience the connectivity 
issues encountered using the previous system, as compo-
nents were more likely to be in range, connected, and operat-
ing in Auto mode.
While most participants reported similar benefits when 
using the app to manage diabetes in schools, several indi-
cated that mobile phone policies had created difficulties, 
particularly if teachers were not familiar with reasons for 
needing to consult the app during lessons. As a result, 
some described using the app covertly: “I just find it eas-
ier just doing it under the table” (Participant#18), or 
checking their glucose levels less often during classes 
because they were not permitted to have a phone on their 
desk (see Table 4).
Better Glycemic Control: Collaborating with the 
Closed-loop Using “Boost” and “Ease-off”
When reflecting on their earlier experiences, participants 
described being able to better manage diabetes and optimize 
glycemic control with the CamAPS FX system because they 
could use the “boost” and “ease-off” functions.
Boost. Individuals noted that the “boost” function provided 
them with “a lot more options to deal with highs” (Partici-
pant#7), including elevated post-prandial glucose levels, 
compared with their experiences using the previous system 
and having to calculate, administer, and check the outcome 
after inputting corrective doses of insulin (see Table 4). Par-
ticipants also described being able to better manage glucose 
excursions resulting from eating high-carbohydrate foods. 
This was because they could “boost” if their glucose levels 
had risen too high or use the function in advance of eating 
high-carbohydrate foods to assist the algorithm’s response to 
rising glucose levels (see Table 4).
Others reported that using “boost” helped them achieve 
better glycemic control if they felt unwell or if their glucose 
levels were unexpectedly high and the algorithm had yet to 
bring them into range: “if I’m sick one day or I’m running 
high for no reason, I’ll put a ‘Boost’ on. . . I’ve noticed that 
[when I’m high] if I don’t have a Boost on, I probably would 
go higher” (Participant#17)
Ease-off. Very few participants recalled using the temporary 
basal “exercise” setting on the pump component forming 
part of the previous system; however, most described rou-
tinely using the “ease-off” function on the closed-loop app 
prior to physical activity because: “it’s [‘ease-off’] just a lot 
simpler and easier to use . . . all of the configuration or any-
thing you need to do is on the app itself” (Participant#3). As 
individuals noted, being able to use this function resulted in 
them feeling less worried about developing hypoglycemia 
when they were physically active (see Table 4).
Alarms
All participants highlighted the benefits of no longer receiving 
calibration alerts, which helped lessen disruptions at night: 
“this system gives you alarms only if you really need them, so 
Table 3. Demographic Characteristics of Study Participants.
Characteristic N % Mean ± SD and range
Adolescents (n = 18)
Female 8 44.4  
Age at interview—all children (years) 14.3 ± 2.1, range 11-18
Diabetes duration (months) 23.7 ± 6.6, range 16-34
Duration using FlorenceM (months) 16.6 ± 6.5, range 8-27
Duration using CamAPS FX (months) 6.3 ± 0.5, range 6-7
Ethnicity
White, British 18 100  
Parents (n = 32)  
Occupation  
 Professional 15 46.9  
 Semi-skilled 13 40.6  
 Unemployed/full-time carer 4 12.5  
Abbreviation: SD, standard deviation.
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Table 4. Participant Quotations.
Theme Participant quotations
Benefits: less work, 
feeling more normal, 
and less stigmatized
Benefits of parents being able to remotely monitor data
it was quite annoying, because it [data] was only on my phone [when using FlorenceM]. So if they wanted 
to look at it, I’d have to stay there for a bit and obviously be next to the phone while they’re looking at it. 
But it’s just easier on theirs [phone], so that they’re not always asking about, you know, ‘let me see your 
phone, let me just check this for a minute’. It’s just easier on their phone (Participant#5)
Less work and effort
you can do like boluses, like on the go. . . . So like say you’re walking in town or something, you can just 
look through it [closed-loop app] there. . . instead of having to like sit down and take it [pump] out. I 
think it’s a lot more like suited to maybe modern lifestyle (Participant#2)
More discreet, less stigmatizing
I used to have to you know, take my pump out, like you could obviously see it, whereas now it only looks 
like I’m on my phone, you know, playing a game or something. . . it doesn’t make as big a deal of it, you 
know, if I’m out [in public] or something (Participant#5).
Better opportunities 
to monitor and 
review glucose 
readings
Monitoring and reviewing glucose levels
I just take it [phone] everywhere with me. . . So when it’s [closed-loop app] in my phone, I have that 
with me anyway, all the time. And I’m mostly on it all the time, like talking to my mum, or talking to my 
friends. So it’s easy to do it [check glucose levels] (Participant#9).
Reviewing data to inform adjustments to insulin doses
I have a look back at me day, see if I’ve been high or low. . . if I’m in school, I’ll have a look at the lunchtime 
and the break-time if I eat. And then if it’s been high the day before, I’d make sure I put in a bit of extra 
carbs the next day (Participant#12).
Use of closed-loop in schools
sometimes in class I have checked but I’ve not like tooken [taken] my phone out of my bag, I’ve just 
looked, like I’ve just did it like, had the phone in my bag and just like done it through putting my hand in 
my bag and like act like I’m looking for something or something like that (Participant#10)
Better glycemic 
control: collaborating 
with the closed-loop 
using Boost and 
Ease-off
Boost: better than using corrections
I kept having to like, I’d get my pump out [when using the previous closed-loop], do a correction, wait a 
few, like 20, 30 minutes. Then I’d check it [glucose level on pump] and I’d be like, ‘oh, I still haven’t gone 
down yet’, so I’d have to do corrections, corrections, corrections. Whereas with this one [CamAPS FX], 
I put a Boost on. . . I’d check my phone and then I just see if I’ve come down (Participant#9)
Boost: dealing with post-prandial high blood glucose levels
if I know what I’m eating, like a high-carb meal and I’m gonna go high after it no matter what I take, I can 
put ‘Boost’ on for it. . . like pasta, chips, em bread. . . With the ‘Boost’ on, it’ll increase the temp basal, 
which is very helpful (Participant#13)
Ease-off: less concerns about developing hypoglycemia
if I was doing PE at school [using the previous closed-loop], then I kept having to worry about going 
low and things like that, which sometimes happen if I’m doing quite intensive sports. But if I was to 
have eased-off [before doing physical activity] then I wouldn’t worry about them [hypos] so much 
(Participant#18)
Alarms Customizing alerts: less stigma
In school I keep my phone [alarms] on vibrate. . . only I can hear it because it’s on my chair. . . So it’s a 
lot less of a you know, it like it doesn’t make a scene or anything . . . it makes it better because nobody 
actually knows (Participant#7)
Customizing and responding to alarms
I’ve turned off the alarms for going high. . . it kept going off when I felt I had it under control, when I didn’t 
feel like I needed to be reminded. It sort of meant I’d hear an alarm and not really react. . . Whereas, 
because I turned it off, it’s like if I hear an alarm now, I know it’s because I’m considerably low, so it’s 
something I really need to check out. (Participant#16)
Unintended 
consequences: 
over-reliance on the 
closed-loop
Less time thinking about diabetes
it improves the way that your life with diabetes is, because you’ve got such good equipment to control 
it, there’s not really much things like finger-pricks or injections to do. . . also because I’ve got a normal 
phone, and it’s my day-to-day phone. And the pump’s a lot lighter, so hardly thinking about that. And 
my sensor’s so easy to put on. So just things like that decrease the amount you think about it [diabetes] 
(Participant#17)
(continued)
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this one’s definitely better for like sleep” (Participant#10). As 
others reported, being able to easily silence alarms helped limit 
the risk of being stigmatized by peers at school (see Table 4).
Many also described benefits from being able to custom-
ize the glucose levels, which would trigger alarms: “I set an 
alert if my blood sugar like say is 4.8, it’ll give me a notifica-
tion, so I can drink some Lucozade. . . before it actually goes 
like really low” (Participant#3) or by deactivating high glu-
cose alerts if they felt confident the closed-loop would bring 
their levels into range. Indeed, as several pointed out, being 
able to configure alarms made it more likely that they would 
respond appropriately when those they had activated were 
triggered (see Table 4).
Unintended Consequences: Over-reliance on the 
Closed-loop
While participants noted that the closed-loop platform had 
alleviated much of the effort and burden associated with dia-
betes management, several indicated that this meant they spent 
less time thinking about diabetes in general (see Table 4). 
These individuals also described how this had resulted in them 
sometimes forgetting to carry out key tasks such as adminis-
tering a bolus for a meal (see Table 4).
Discussion
The CamAPS FX system32 addresses many of the barriers to 
access and usability issues reported by (adolescent) users of 
previous closed-loop systems,20,25-29 CGMs,24,34 and insulin 
pumps.35,36 Usability is a key factor in determining closed-
loop use, and higher usage has been shown to be associated 
with improved glycemic outcomes and lower HbA1c.20,21 
The improved usability features of CamAPS FX may there-
fore help to address age-related health disparities experi-
enced by adolescents who have type 1 diabetes. Adolescent 
participants described feeling less shackled and burdened by 
diabetes by virtue of using a system with components which 
were easy to carry and/or wear. Additional quality-of-life 
benefits resulted from no longer needing to undertake finger-
prick checks and/or respond to requests from parents to pro-
vide information about glucose levels. Participants also 
described benefiting from using a control algorithm that 
resided on a smartphone app, as this enabled them to check 
glucose and administer insulin effortlessly and in ways that 
did not draw attention to them having diabetes; the ability to 
customize and deactivate alarms was also praised in this 
regard. Adolescents further highlighted how self-manage-
ment practices and sense of control over their condition had 
been aided by being able to easily review glucose data and 
adjust closed-loop insulin delivery using the “boost” and 
“ease-off” functions. While the new system addresses many 
of the accessibility and usability issues reported by users of 
previous iterations of the technology, it could potentially 
result in adolescents forgetting about diabetes and neglecting 
to undertake some key tasks.
Studies have shown how family conflicts can result when 
adolescents neglect to perform tasks such as checking blood 
glucose levels, which can act as barriers to achieving optimal 
glycemic control.37,38 As our findings illustrate, adolescents 
using this closed-loop system may experience lessened family 
conflict because of no longer needing to do finger-pricks and 
parents being able to monitor their glucose data remotely; the 
latter benefit has also been reported by CGM users and their 
caregivers.38,39 Research involving adolescents using MDI and 
insulin pump regimens has also highlighted how self-manage-
ment tasks, such as regular finger-prick checks and adminis-
tering insulin, can be neglected due to wanting to avoid 
unwanted attention from peers and resulting stigma.14,40-44 As 
well as being able to perform these tasks discreetly by virtue of 
the app being on a smartphone, participants described having 
checked their data more frequently because they did so oppor-
tunistically when using their smartphone for other reasons (eg, 
sending texts).
As others have shown, adolescents who do not receive 
appropriate support from teachers can hide or neglect diabe-
tes tasks at school.45,46 While participants in our study 
described benefitting from using a medical app on an 
unlocked smartphone, some also highlighted challenges to 
accessing and using this aspect of the technology in school 
settings where use of smartphones is not normally permitted. 
Similar issues might also arise for other groups, such as 
adults working in customer-facing roles, where use of smart-
phones may not be permitted or considered appropriate. It 
Theme Participant quotations
Forgetting to perform key tasks
it’s almost too easy. It’s – it’s a victim of like its own success in that way, in that like it’s so easy that maybe 
you don’t pay full attention. . . or you’re not hyper like concentrated and worried. Like I think that’s 
a good thing in some ways but it’s sort of, like, it’s too good, so maybe your focus isn’t quite there. 
(Participant#16)
Interviewer: “In what ways do you feel that your focus might be affected by the system being as good as it is?”
yeah, yeah someti- I will sometimes em, I might sometimes just forget to put in the bolus, but it’s not- I 
don’t do it particularly often, but I do sometimes- sometimes if I’m tired I will. (Participant#16)
Table 4. (continued)
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has been suggested that users be given the choice of using a 
phone-based or pump-based control system according to 
their needs.47 To maximize accessibility, developers of future 
systems that use an app-based controller could consider pro-
viding users with the option to switch to a pump-based con-
trol system when in school and other settings where use of 
phones is discouraged. In addition, current guidelines48,49 
should be updated to ensure school staff are provided with 
training to facilitate better understanding and provision of 
support to young people using closed-loop systems and dia-
betes smartphone apps.
In earlier studies, adolescents have reported seeking ways 
to communicate with and customize closed-loop systems, 
including being able to announce plans for physical activity 
or atypical days,13,31 or reduce “alarm fatigue.”13,31 As our 
findings illustrate, participants noted particular benefits to 
being able to collaborate with the closed-loop system. This 
included using the “boost” function to better address hyper-
glycemia at mealtimes or if they were unwell, and the “ease-
off” function, which helped lessen anxieties about developing 
hypoglycemia when doing physical activity. Similar to find-
ings from previous studies,13,30 we have illustrated how the 
reduced frequency of, and ability to personalize, alarms 
resulted in participants experiencing better sleep and 
improved quality of life due to less disruption at school, 
when in bed or in public settings. Importantly, our findings 
suggest that users may be more likely to respond to alarms 
when they can customize glucose thresholds and choose 
which ones to activate.
A key study strength is that it involved adolescents with 
≥6 month’s experience using a closed-loop system in “real-
life” settings, which provided a greater level of insight than 
earlier studies of shorter durations.26,27,29,30,50,51 Although our 
sampling took account of adolescents’ parents’ occupations, a 
potential limitation is our lack of representation of individuals 
from minority ethnic backgrounds, which reflected low repre-
sentation of these groups in the wider trial. This might limit 
the generalizability of some of our findings. It should also be 
noted that our study, like others,50 included participants who 
described how the closed-loop system lessened the burdens of 
self-management to the extent that they could sometimes for-
get they had diabetes, resulting in them neglecting to perform 
some key diabetes tasks. Consequently, future studies could 
use longer periods of follow-up to establish whether these 
issues manifest and persist when individuals use closed-loop 
systems over time. It should also be noted that our sample 
comprised participants who had used a closed-loop since 
diagnosis. Hence, future research could consider individuals 
who have transitioned from MDI or insulin pump regimens, 
who, in light of these previous experiences, may perceive 
other or additional benefits to using closed-loop technology. 
Further research could also explore the views and experiences 
of health professionals involved in delivering care and pro-
viding support to users of the CamAPS FX system.
Conclusions
In conclusion, our study has demonstrated how a closed-loop 
platform with small components and a control interface 
hosted on a smartphone app can help to optimize glycemic 
benefits and address accessibility and usability issues experi-
enced by adolescent users of earlier iterations of the technol-
ogy. Our findings also identify some challenges to using a 
medical app on a device which doubles as a personal smart-
phone. To maximize accessibility and usability among ado-
lescents who use closed-loop systems, and consequently to 
help address the health-related disparities experienced by 
this age group, we recommend that future iterations incorpo-
rate or retain the features described above.
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